The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation

Therapeutics that block tumor necrosis factor (TNF), and thus activation of TNF receptor 1 (TNFR1) and TNFR2, are clinically used to treat inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. However, TNFR1 and TNFR2 work antithetically to balance immune resp...

Descripció completa

Dades bibliogràfiques

Autors principals:	Fabian Richter, Sarah K. Williams, Katharina John, Carina Huber, Camille Vaslin, Henri Zanker, Richard Fairless, Kira Pichi, Silke Marhenke, Arndt Vogel, Marie-Ann Dhaen, Stefanie Herrmann, Andreas Herrmann, Klaus Pfizenmaier, Heike Bantel, Ricarda Diem, Roland E. Kontermann, Roman Fischer
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2021-07-01
Col·lecció:	Frontiers in Immunology
Matèries:	TNF TNFR1 inflammatory diseases arthritis EAE multiple sclerosis
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.705485/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!